Hyperion Capital Advisors LP Makes New $728,000 Investment in West Pharmaceutical Services, Inc. $WST

Hyperion Capital Advisors LP acquired a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 2,029 shares of the medical instruments supplier’s stock, valued at approximately $728,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Addison Advisors LLC bought a new position in shares of West Pharmaceutical Services during the second quarter worth $28,000. Avalon Trust Co bought a new stake in West Pharmaceutical Services in the 2nd quarter valued at $28,000. Elyxium Wealth LLC purchased a new stake in West Pharmaceutical Services in the 4th quarter worth $25,000. Bayban bought a new position in shares of West Pharmaceutical Services during the 4th quarter valued at about $27,000. Finally, DV Equities LLC bought a new position in shares of West Pharmaceutical Services during the 4th quarter valued at about $28,000. Institutional investors own 93.90% of the company’s stock.

Wall Street Analyst Weigh In

WST has been the topic of several research reports. BNP Paribas Exane initiated coverage on West Pharmaceutical Services in a report on Monday, July 13th. They issued an “outperform” rating and a $447.00 target price on the stock. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a research note on Wednesday, July 15th. Evercore restated an “outperform” rating and set a $425.00 price target on shares of West Pharmaceutical Services in a report on Monday, July 27th. Zacks Research downgraded West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, Citigroup upped their price objective on West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, West Pharmaceutical Services presently has an average rating of “Moderate Buy” and an average target price of $368.08.

West Pharmaceutical Services Stock Up 0.1%

Shares of NYSE:WST opened at $353.33 on Tuesday. The company has a market cap of $24.87 billion, a price-to-earnings ratio of 45.24, a PEG ratio of 2.47 and a beta of 1.15. West Pharmaceutical Services, Inc. has a 12 month low of $223.83 and a 12 month high of $386.00. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average price of $349.06 and a 200 day moving average price of $301.06.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company had revenue of $872.30 million for the quarter, compared to analysts’ expectations of $839.98 million. During the same period in the previous year, the firm posted $1.84 earnings per share. The firm’s revenue for the quarter was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, equities research analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were given a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. West Pharmaceutical Services’s payout ratio is currently 11.27%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.